Your browser doesn't support javascript.
loading
Impairment in Functioning and Quality of Life in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE).
Stevens, Joanne; Schneider, Logan D; Husain, Aatif M; Ito, Diane; Fuller, Douglas S; Zee, Phyllis C; Macfadden, Wayne.
Affiliation
  • Stevens J; Global Medical Affairs, Jazz Pharmaceuticals, Philadelphia, PA, USA.
  • Schneider LD; Stanford University Sleep Medicine Center, Stanford University School of Medicine, Stanford, CA, USA.
  • Husain AM; Duke University Department of Neurology, Duke University Medical Center, Durham, NC, USA.
  • Ito D; Stratevi, Santa Monica, CA, USA.
  • Fuller DS; Biostatistics, Jazz Pharmaceuticals, Philadelphia, PA, USA.
  • Zee PC; Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Macfadden W; Global Medical Affairs, Jazz Pharmaceuticals, Philadelphia, PA, USA.
Nat Sci Sleep ; 15: 593-606, 2023.
Article in En | MEDLINE | ID: mdl-37551277
ABSTRACT

Purpose:

Idiopathic hypersomnia is a debilitating neurologic sleep disorder characterized by excessive daytime sleepiness, sleep inertia, and prolonged sleep. Its impact on patients' quality of life and daily functioning has not been fully elucidated. The Real World Idiopathic Hypersomnia Outcomes Study (ARISE) evaluated the daily functioning, relationships, cognition, emotional well-being, and productivity/employment of participants with idiopathic hypersomnia. Patients and

Methods:

ARISE was a US-based virtual cross-sectional survey comprising multiple patient-reported outcome measures (Functional Outcomes of Sleep Questionnaire, short version [FOSQ-10], Quality of Life in Neurological Disorders [Neuro-QoL] Social Roles and Stigma domains, British Columbia Cognitive Complaints Inventory [BC-CCI], Patient Health Questionnaire [PHQ-9], and the Work Productivity and Activity Impairment Questionnaire Specific Health Problem [WPAISHP]). Participants were adults 21-65 years of age with idiopathic hypersomnia. Data were analyzed for all participants and for subgroups with/without long sleep time (LST; self-reported sleep ≥11 hours in 24 hours).

Results:

Of 75 participants enrolled, most were female (81.3%) and the mean (SD) age was 34.1 (10.7) years. Participants' scores on the FOSQ-10 (mean [SD] score 10.7 [2.8]) and the Neuro-QoL Social Roles (43.4 [4.2]) and Stigma (57.3 [5.9]) domains reflected impairments in daily functioning and quality of life. More than half of participants reported moderate to severe cognitive complaints (BC-CCI; 62.7%) and moderate to severe depressive symptoms (PHQ-9; 66.7%). Scores on the WPAISHP showed substantial impairments in absenteeism, presenteeism, overall work productivity, and overall regular daily activity (mean percent [SD] 12.3 [23.6], 47.6 [22.7], 51.4 [24.7], and 64.0 [21.9], respectively). These considerable impairments were found in participants with and without LST.

Conclusion:

ARISE participants with idiopathic hypersomnia demonstrated poor quality of life and impaired functioning across multiple symptom domains.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Sci Sleep Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Sci Sleep Year: 2023 Type: Article Affiliation country: United States